NXDC is a privately owned life science company dedicated to the commercial launch of Gleolan in the United States as a real time imaging agent allowing surgeons to visualize brain tumors during surgery.
To bring Gleolan to the surgical community to enhance the upfront management of patients with glioblastoma. The use of Gleolan to visualize structural elements related to tumor presentation and enable the surgeon to make real time decisions about tumor de-bulking has become a standard in other countries and is envisioned to be well received in the US at time of commercial launch.
What We've Achieved
The company is currently planning to submit a New Drug Application to the FDA H2 2016 and is currently working with advisers and key surgeons to ensure fast track approval and commercial launch.